- In June 2022, Gufic Biosciences Ltd introduced an innovative dual-chamber drug delivery system in India, designed for intravenous (IV) administration. These advanced IV bags are constructed from polypropylene and feature peelable aluminum foil. They are specifically designed for storing unstable drugs that require reconstitution just before being administered to patients, enhancing safety and efficiency in medical treatments
- In 2022, The World Health Organization reported that approximately 39 million people were living with HIV globally, including 1.5 million children aged 0-14. In 2022, 630,000 people died from HIV-related causes, but 29.8 million people were on antiretroviral therapy. These statistics underscore the increasing demand for advanced drug delivery systems to manage HIV treatment effectively
- In 2023, the U.S. FDA approved ZYNTEGLO, a breakthrough microneedle patch designed to deliver the anti-nausea drug thioperamide for managing post-surgery sickness. This approval marks a significant advancement in drug delivery technologies, offering a non-invasive and effective solution to address nausea in post-operative patients, demonstrating the growing potential of microneedle therapies
- In 2022, Buzzy Patch, launched in 2022, is a pioneering microneedle patch designed to alleviate pain by gradually releasing lidocaine, a local anesthetic. The patch offers a non-invasive and user-friendly method for pain management, particularly in clinical settings where needles or injections are typically required. Its gradual release of lidocaine enhances patient comfort during treatment
- In March 2022, Eucure Biopharma, a subsidiary of Biocytogen, disclosed the first patient dose for a phase I clinical trial in Australia, testing YH002, an anti-OX40 monoclonal antibody, in combination with YH001, an anti-CTLA-4 monoclonal antibody. The trial aims to explore the efficacy and safety of these promising treatments in advanced cancers, marking an important milestone in oncology research
- In February 2022, Transcenta Holding Limited initiated phase IIa clinical trials in February 2022 to investigate TST001, a claudin 18.2 monoclonal antibody, in combination with cisplatin and gemcitabine as a first-line therapy for biliary tract cancer. This research aims to improve treatment outcomes for patients suffering from this aggressive and often difficult-to-treat cancer type, offering hope for new therapeutic approaches
